NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
PICKERING, Ontario, May 08, 2018 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce that its Abba Medix Corp. (“Abba”) subsidiary has planted its first crop of high grade medicinal cannabis seeds at the Company’s Health Canada Licensed (LP) Pickering grow facility. Eight strains were chosen for this first planting to meet the medicinal needs of its sister firm Marijuana for Trauma (“MFT”) and their thousands of clients across Canada.
“We’re very excited to finally begin our first growing cycle,” said Abba President Riley McGee. “We are focused on growing the finest medicinal cannabis strains available for MFT’s patient network. This is a major step in continuing to build our unique-in-the-industry integrated cannabis company.”
At full production, Abba’s Pickering facility is projected to produce more than 2,100 kg of premium cannabis bud annually. Abba is expected to reach full production and obtain a license to sell by the end of this year.
Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit https://www.canadahouse.ca. or www.sedar.com
For further information, please contact:
Boom Capital Markets
Canada House Wellness Group, Inc.
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.